Now I have a comprehensive understanding of the paper and all reviewer perspectives. Let me synthesize the final review.

## Summary

This paper proposes an end-to-end framework for multi-view diabetic retinopathy (DR) grading that eliminates the need for costly external lesion/vessel annotations. The core idea is a Grade-Activated Lesion Proposal (GALP) module that derives grade-conditioned evidence maps from auxiliary classifiers and selects top-K regions as self-generated "lesion proposals," combined with a Cross-View Lesion Expert Guided Regional Fusion (LGRF) module that uses Mixture-of-Experts routing to selectively fuse proposals across views. On two multi-view DR benchmarks (MFIDDR and DRTiD), the lesion-free variant matches or surpasses several externally-informed baselines.

## Strengths

- **Well-motivated problem with practical significance.** The paper identifies a real limitation — external lesion/vessel annotations are costly and introduce brittle upstream dependencies — and proposes a self-contained solution that preserves end-to-end training while closing the gap with annotation-dependent methods.

- **Solid performance improvement over end-to-end baselines.** On MFIDDR, the lesion-free variant (83.9% Acc, 70.9% Kappa, 83.5% F1) significantly outperforms all prior end-to-end methods (best prior: ETMC at 81.5% Acc) and even surpasses some externally-informed methods (CVSA-w/vessel: 82.6%, LFMVDR-w/lesion: 82.2%). On DRTiD, it outperforms CrossFiT (76.0 vs 75.6% Acc) without requiring OD/macula coordinates. These are meaningful gains over purely end-to-end baselines.

- **Meaningful ablation study.** Table 4 cleanly shows that each component (GALP: −1.2% Acc when removed; Experts: −1.3%; LGRF: −1.6%) contributes to the overall result, confirming they are not redundant.

- **Architectural design has genuine novelty in application context.** While CAMs and MoE are individually established, their combination for self-supervised "lesion proposal" generation in multi-view DR grading is novel. The idea of using grade-conditioned CAMs as internal cues to guide cross-view fusion is conceptually appealing and could inspire follow-up work.

- **Graceful compatibility with external information when available.** The framework's "w/ lesion" variant (84.6% Acc, 72.3% Kappa) establishes a new SOTA on MFIDDR, showing the architecture is not antagonistic to auxiliary signals.

## Weaknesses

### Major:

- **"Lesion proposal" interpretation is asserted but not validated.** The paper's central conceptual move is to treat top-K CAM patches as "lesion proposals" and claim they are "effective surrogates for expert cues." However, CAMs highlight grade-discriminative regions, which can include vessels, optic disc, artifacts, or global contrast patterns — not just lesions. The MFIDDR dataset provides lesion segmentation masks (which the authors use in their "w/ lesion" variant), yet no quantitative evaluation (e.g., IoU, recall/precision of proposals vs. ground-truth lesion regions) is provided. Without validating that these proposals actually localize lesions, the "lesion proposal" framing and interpretability claims are unsupported, and the gain over baselines could simply come from attention to grade-discriminative regions (not specifically lesions) plus auxiliary supervision.

- **The "substantially reduces annotation dependence" claim is stronger than the evidence warrants.** On MFIDDR, the best annotation-based methods (WGLIN: 84.2% Acc, SMVDR-M: 84.0%) still outperform the lesion-free variant (83.9%); the gaps in Kappa and F1 are ≈0.3–0.5 points. On DRTiD, the improvement over CrossFiT is 0.4% Acc (76.0 vs 75.6). No standard deviations, confidence intervals, or significance tests are reported for any comparison. The results are *competitive* with externally-informed methods — which is valuable — but the rhetoric of "substantially reduces dependence" and "effective surrogates" overstates the evidence. This framing matters because it is the paper's central motivation.

- **No ablation isolating auxiliary classification loss from the proposal mechanism.** GALP combines two effects: (a) stage-wise auxiliary supervision (deep supervision, a well-known regularizer) and (b) top-K proposal selection for cross-view fusion. The ablation in Table 4 removes GALP entirely (dropping both effects). A "w/ aux loss but w/o proposals" variant is needed to determine how much gain comes from deep supervision vs. the actual proposal mechanism. Without this, it is unclear whether the performance improvement is driven by the proposal architecture or simply by stronger feature learning from auxiliary losses.

### Minor:

- **No per-grade stratified analysis for early-stage DR.** The paper claims to recover "small, low-contrast lesions (e.g., microaneurysms)," but all metrics are image-level. Grade 1 (mild DR) has the lowest F1 (69.7% w/o lesion) and the smallest improvement from lesion proposals. No targeted analysis (e.g., sensitivity to micro-lesion cases vs. obvious pathology) is provided to substantiate the micro-lesion sensitivity claim.

- **Computational cost is not reported.** The model adds auxiliary heads at three stages, top-K proposal selection, MoE routing with 6 experts, and cross-view attention. No FLOPs, parameter counts, or inference times are provided, making it difficult to assess the cost-benefit trade-off relative to simpler baselines.

- **Adjacent-view-only fusion is unjustified.** LGRF fuses view i only with view j=i+1 (cyclic). In a four-view setting, this means non-adjacent view pairs never directly interact. This design choice lacks ablation or justification (e.g., comparing with all-pairs fusion).

- **No analysis of expert specialization.** The MoE routing is a core component, but no investigation is provided into whether different experts actually specialize (e.g., for different lesion types or views), or whether the gating degenerates to always selecting the same experts.

### Trivial:

- **No limitations section or discussion of failure modes.** The conclusion restates strengths without acknowledging weaknesses such as the modest gap with annotation-based SOTA, potential failure modes of CAM proposals, or generalizability beyond two DR datasets with similar characteristics.

## Nice-to-Haves

- **Lesion-level validation of proposals:** Overlay GALP-derived proposals on fundus images with ground-truth lesion masks and compute IoU/recall/precision. This is the single most impactful addition that would substantiate the paper's central claim.

- **Ablation separating auxiliary loss from proposals:** Add "w/ aux loss only" (no top-K selection, no proposal fusion) to Table 4.

- **Report mean ± std over multiple runs:** Especially important given the small margins in some comparisons (e.g., 76.0 vs 75.6 on DRTiD).

- **Simple cross-attention fusion baseline:** Compare against a straightforward multi-view Swin-B with standard cross-attention (no proposals, no experts) to isolate the contribution of the proposal+expert mechanism beyond architectural depth.

- **Computational cost analysis:** Report FLOPs, parameters, and inference time for the full model vs. key baselines.

## Removed Points

These points are flagged to be removed; treat them with caution.

- **"Incremental module combination" — the novelty concern from the human finder.** The human finder cited a rejected CAM-based visual grounding paper to claim the method is "an easy combination" of established techniques. This is an unfair comparison context — the combination in this paper (CAM-derived proposals with MoE-gated cross-view fusion for DR grading) is application-novel and technically non-trivial. Novelty concerns in application domains should be evaluated against the specific field's standards. KEEP the point that the components are established, but REMOVE the characterization as "incremental" or "easy combination."

- **"Limited evaluation on only two datasets."** The human finder raised this by analogy to other papers. For the multi-view DR grading domain, there are only two established multi-view benchmarks (MFIDDR and DRTiD), both of which the paper uses. Evaluating on both existing benchmarks is the standard practice; demanding more is unreasonable scope creep.

- **"Missing training hyperparameter details for reproducibility."** The paper specifies backbone (Swin-B), pretraining datasets, learning rate weight for auxiliary and load-balancing losses, patch sizes, retention ratio, expert count, and optimizer setup in Section 4.1. This level of detail is standard for the field. Nitpicking unspecified details like batch size or exact augmentation pipeline is not a substantive weakness.

- **Demanding generalizability to other medical imaging modalities or non-DR tasks.** The paper is explicitly about multi-view DR grading. Criticizing it for not generalizing to other modalities or diseases is scope creep.

- **"Multiple hyperparameters with limited sensitivity analysis" beyond K₁, K₂, M.** The paper provides sensitivity analysis for the three most important hyperparameters (retention ratio, K₂ experts, M total experts). λ_aux is set equal to λ_cls (a natural choice) and λ_load=0.1 is standard from MoE literature. Demanding exhaustive sweeps of all hyperparameters is beyond what the community expects.

## Novel Insights

The key insight that emerges from combining the reviewers' perspectives is a disconnection between the paper's *framing* and its *evidence*. The method's actual contribution is a technically sound end-to-end multi-view DR grading architecture that achieves solid performance improvements over prior end-to-end baselines. The "lesion proposal" narrative — while conceptually appealing — is not validated as such; what GALP actually provides is attention to grade-discriminative regions via CAM, which may or may not correspond to lesions. The paper would be substantially stronger if it either validated the lesion-localization claim empirically (the data exists: MFIDDR has lesion masks) or reframed the contribution more honestly as "grade-activated attention for cross-view fusion" rather than "lesion proposals as surrogates for expert cues." The auxiliary loss confound is also an important gap — without it, we cannot determine whether the proposal mechanism itself drives performance or whether deep supervision does the heavy lifting.

## Suggestions

- **Validate proposal quality against lesion masks.** Compute the overlap between GALP's top-K proposals and ground-truth lesion regions in MFIDDR. Even a simple IoU or pixel-level recall analysis would transform the paper's conceptual claim from assertion to evidence.

- **Add "auxiliary loss only" ablation.** Include a variant in Table 4 that keeps the auxiliary classification loss but replaces top-K proposal selection with using all tokens for LGRF fusion. This cleanly separates deep supervision from the proposal mechanism.

- **Soften the framing.** Replace "substantially reduces dependence" with "reduces dependence" or "partially closes the gap," and replace "lesion proposals" with "grade-activated proposals" in claims where lesion-specific evidence is not provided.

- **Report variance across seeds.** Run 3–5 seeds and report mean ± std to establish robustness of the improvements.

- **Add a simple cross-attention baseline** (Swin-B multi-view with standard cross-attention, no proposals/experts) to isolate the value added by the GALP/LGRF architecture beyond model depth.

## Score and Decision

**Calibration comparison:**

- **M4oE (multi-modal MoE medical imaging)** — Scores 5,6,6,6 → Accept Poster. Similar pattern: complex MoE model, modest improvements, no variance reporting. Our paper has stronger empirical results relative to more baselines but similar concerns about complexity justification and statistical rigor.

- **Multi-view classification with multi-scale alignment (t1J2CnDFwj)** — Scores 5,5,5,8 → Accept Poster. Similar domain (multi-view), moderate complexity, comparable novelty concerns. Our paper's domain specificity (DR) and practical relevance are advantages.

- **Weakly supervised medical lesion segmentation (8g5Ye3c3oR)** — Scores 3,5,5,5 → Reject. This had weak novelty, poor baselines, and unclear methodology. Our paper is significantly stronger with better experiments and clearer architecture.

- **Point-supervised medical segmentation (6NO5UVWvo6)** — Scores 3,5,5,5 → Reject. Similar annotation-efficiency angle but weaker methodology.

- **fVLM (large-scale vision-language pre-training)** — Scores 6,8,8,8 → Accept Spotlight. Significantly stronger novelty and scale of contribution. Our paper does not reach this level.

The paper makes a genuine contribution with a well-engineered architecture that clearly outperforms end-to-end baselines and competes with annotation-dependent methods. However, two major weaknesses — unvalidated "lesion proposal" interpretation and the unseparated auxiliary loss confound — undermine the conceptual framing, which is the paper's primary selling point. The performance over prior end-to-end methods is solid (2–3% Acc improvement on MFIDDR), but the claims about replacing expert annotations and micro-lesion sensitivity overreach the evidence. This sits squarely in the "good but needs revision" category for a top venue.

MY FINAL SCORE: <pineapple>5.5</pineapple>
MY FINAL DECISION: <orange>Reject</orange>